- Home
- PFE vs AMGN Comparison
PFE vs AMGN Comparison
Compare PFE & AMGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PFE
- AMGN
- Stock Information
- Founded
- PFE 1849
- AMGN 1980
- Country
- PFE United States
- AMGN United States
- Employees
- PFE N/A
- AMGN N/A
- Industry
- PFE Biotechnology: Pharmaceutical Preparations
- AMGN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PFE Health Care
- AMGN Health Care
- Exchange
- PFE Nasdaq
- AMGN Nasdaq
- Market Cap
- PFE N/A
- AMGN 156.2B
- IPO Year
- PFE N/A
- AMGN N/A
- Fundamental
- Price
- PFE $25.70
- AMGN $311.37
- Analyst Decision
- PFE Buy
- AMGN Buy
- Analyst Count
- PFE 14
- AMGN 21
- Target Price
- PFE $31.92
- AMGN $323.26
- AVG Volume (30 Days)
- PFE 56.3M
- AMGN 3.2M
- Earning Date
- PFE 04-29-2025
- AMGN 05-01-2025
- Dividend Yield
- PFE 6.73%
- AMGN 3.10%
- EPS Growth
- PFE 284.33
- AMGN N/A
- EPS
- PFE 1.41
- AMGN 7.56
- Revenue
- PFE $63,627,000,000.00
- AMGN $33,424,000,000.00
- Revenue This Year
- PFE $0.06
- AMGN $7.36
- Revenue Next Year
- PFE $0.13
- AMGN $2.18
- P/E Ratio
- PFE $18.10
- AMGN $40.58
- Revenue Growth
- PFE 6.84
- AMGN 18.57
- 52 Week Low
- PFE $24.48
- AMGN $253.30
- 52 Week High
- PFE $31.54
- AMGN $346.85
- Technical
- Relative Strength Index (RSI)
- PFE 48.35
- AMGN 52.70
- Support Level
- PFE $25.89
- AMGN $311.16
- Resistance Level
- PFE $26.52
- AMGN $317.58
- Average True Range (ATR)
- PFE 0.47
- AMGN 6.38
- MACD
- PFE 0.01
- AMGN -1.61
- Stochastic Oscillator
- PFE 30.75
- AMGN 12.37
About AMGN Amgen Inc.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.